Progress in Fibrin Sealing
- PDF / 15,189,815 Bytes
- 151 Pages / 482 x 692 pts Page_size
- 35 Downloads / 241 Views
(Ed.)
Progress in Fibrin Sealing With 95 Figures and 19 Tables
Springer-Verlag Berlin Heidelberg New York London Paris Tokyo
Univ. Doz. Dr. Hans-Werner Waclawiczek 1. Chirurgische Abteilung, Landeskrankenanstalten Salzburg, Miillner Hauptstrafie 48, A - 5020 Salzburg
ISBN-13: 978-3-540-50797-0 e-ISBN-13: 978-3-642-48362-2 DOl: 10.1007/978-3-642-48362-2 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this pUblication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law.
© Springer-Verlag Berlin Heidelberg 1989 The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. Typesetting: Daten- und Lichtsatz Service, Wlirzburg Offsetprinting: Saladruck, Berlin. Bookbinding: Llideritz & Bauer, Berlin 2127/3020-543210 - Printed on acid-free paper
Preface
Fibrin plays a central role in wound healing. It has a hemostatic effect by forming a temporary wound closure and assists in neovascularization and fibroblast proliferation. It therefore makes the repair of injured or severed parts of the human body by simple glueing possible, a notion that men have dreamed of since ancient times. The first modern attempts in this direction, using clotting substances derived from human blood to achieve hemostasis, were reported by Bergel (in 1909), Grey (in 1915), and Harvey (in 1916), who used fibrin powder or fibrin patches to control bleeding from parenchymatous organs. Two decades later Young and Medawar (1940) and Cronkite (1944) used blood plasma or fibrin solutions, adding thrombin to seal nerve anastomoses and to fix skin grafts in humans. Due to the poor adhesive strength of the fibrinogen the results were unsatisfactory. In 1972 a new era in fibrin sealing was initiated by Matras. By using highly concentrated fibrinogen in combination with factor XIII (fibrin-stabilizing factor) and by delaying fibrinolysis with a fibrinolysis inhibitor (aprotinin), a method was developed which after satisfactory results in animals, soon began to be applied in humans. These initial experiments led to the development of the two-component fibrin sealant Tissucol (Tisseel) by Immuno in 1975. This fibrin sealant is available as a kit containing freeze-dried sealer protein
Data Loading...
